Health Care • Biotechnology: Biological Products (No Diagnostic Substances)
$0.47 ▼ +0.00
(-0.06%)
MKT CAP: $130.5M • VOL: 3.70M
52W L $0 52W H $2
ROARABLE / RQD
E • 31/100
PIOTROSKI
2 / 9
HUMA // SEC EDGAR XBRL STANDARDIZED FINANCIAL STATEMENTS (FA <GO>)
| LINE ITEM (USD / %) | FY 2025
FILED 2025-12-31 | FY 2024
FILED 2024-12-31 | FY 2023
FILED 2023-12-31 |
|---|---|---|---|
| Revenue (Total Sales) | $2.0M | $0 | $0 |
| YoY Revenue Growth % | — | — | — |
| Gross Profit | -$7.7M | — | — |
| Gross Margin % | -50.0% | — | — |
| Research & Development (R&D) | — | — | — |
| Operating Income (EBIT) | -$108.1M | -$114.4M | -$100.0M |
| Operating Margin % | -80.0% | — | — |
| Net Income (GAAP) | -$40.8M | -$148.7M | -$110.8M |
| EBITDA (Normalized) | -$107.4M | -$113.1M | — |
| Diluted EPS ($/sh) | — | — | — |
| Operating Cash Flow (OCF) | -$105.0M | -$98.1M | -$73.3M |
| Capital Expenditures (CapEx) | $884.0K | $1.6M | — |
| Free Cash Flow (FCF) | -$105.9M | -$99.7M | -$73.3M |
| FCF Margin % | -80.0% | — | — |
| Return on Invested Capital (ROIC %) | -45.0% | -45.0% | — |
| Cash & Short-Term Equivalents | $50.5M | $44.9M | — |
| Total Debt (Short + Long Term) | — | — | — |
| Total Stockholders' Equity | $3.1M | -$52.7M | — |
NO QUARTERLY 10-Q XBRL STATEMENTS AVAILABLE IN CURRENT CACHE FOR HUMA.